These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26364029)

  • 1. Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers.
    Arellano-Rodrigo E; Lopez-Vilchez I; Galan AM; Molina P; Reverter JC; Carné X; Villalta J; Tassies D; Lozano M; Díaz-Ricart M; Escolar G
    Transfus Med Rev; 2015 Oct; 29(4):242-9. PubMed ID: 26364029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.
    Escolar G; Arellano-Rodrigo E; Lopez-Vilchez I; Molina P; Sanchis J; Reverter JC; Carne X; Cid J; Villalta J; Tassies D; Galan AM; Diaz-Ricart M
    Circ J; 2015; 79(2):331-8. PubMed ID: 25482382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idarucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemostasis.
    Arellano-Rodrigo E; Fernandez-Gallego V; López-Vilchez I; Molina P; Díaz-Ricart M; Zafar MU; Badimon JJ; van Ryn J; Escolar G
    Transfusion; 2019 Jul; 59(7):2436-2445. PubMed ID: 30946491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban.
    Ibrahim F; Calmette L; Layka A; Horellou MH; Mazoyer É; Gouin-Thibault I; Flaujac C
    Ann Biol Clin (Paris); 2016 Aug; 74(4):457-64. PubMed ID: 27492699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
    Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversing the anticoagulation effects of dabigatran.
    Dager WE; Banares L
    Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
    Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
    PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
    Weisshaar S; Litschauer B; Gouya G; Mayer P; Smerda L; Kapiotis S; Kyrle PA; Eichinger S; Wolzt M
    J Thromb Haemost; 2014 Nov; 12(11):1850-60. PubMed ID: 25211369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
    Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
    Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
    Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
    Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation.
    Kauffmann S; Chabanne R; Coste A; Longeras F; Sinegre T; Schmidt J; Samama CM; Constantin JM; Lebreton A
    A A Case Rep; 2015 Jun; 4(11):151-4. PubMed ID: 26035221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening test for direct oral anticoagulants with the dilute Russell viper venom time.
    Pratt J; Crispin P
    Eur J Haematol; 2018 Jun; 100(6):567-574. PubMed ID: 29486103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.
    Grottke O; Aisenberg J; Bernstein R; Goldstein P; Huisman MV; Jamieson DG; Levy JH; Pollack CV; Spyropoulos AC; Steiner T; Del Zoppo GJ; Eikelboom J
    Crit Care; 2016 Apr; 20(1):115. PubMed ID: 27125504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rivaroxaban and dabigatran on platelet functions: in vitro study.
    Jourdi G; Bachelot-Loza C; Mazoyer E; Poirault-Chassac S; Duchemin J; Fontenay M; Gaussem P
    Thromb Res; 2019 Nov; 183():159-162. PubMed ID: 31678711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Rivaroxaban-Anticoagulated Blood Using Hemostatic Agents.
    Bar J; David A; Khader T; Mulcare M; Tedeschi C
    Prehosp Disaster Med; 2017 Oct; 32(5):580-587. PubMed ID: 28625215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
    Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban: A Multicenter Evaluation.
    Pahs L; Beavers C; Schuler P
    Crit Pathw Cardiol; 2015 Jun; 14(2):53-61. PubMed ID: 26102014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.